Refine by
Therapeutic Potential Articles & Analysis
143 news found
Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. ...
Glis2 is a critical component of the cilia-dependent cyst activation (CDCA) pathway and has emerged as a potential therapeutic target for ADPKD. This application note highlights the use of the Precellys Evolution tissue homogenizer to prepare normal and cystic kidney tissues from various mouse models of ADPKD. ...
The AI-powered system evaluates important characteristics, such as binding affinity and pharmacokinetics, to refine compounds and enhance their therapeutic potential. This iterative process facilitates the creation of drug candidates that not only show promise in early trials but are also more likely to advance through the rigorous drug development pipeline. ...
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, animal models that closely mimic the ...
The company has introduced a state-of-the-art approach to enhance the precision and efficiency of delivering therapeutic antibodies directly to targeted sites, aiming to boost therapeutic efficacy while reducing unwanted side effects. ...
Historically, natural products have played a pivotal role in traditional healing systems, and modern science continues to exploit these compounds for their therapeutic potentials, particularly in combating cancerous and infectious diseases. ...
A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. This innovation not only targets the root cause of inflammation but also leverages advanced delivery and lung function systems like the flexiVent to optimize treatment efficacy. ...
A breakthrough in CD formulation has enabled researchers to evaluate the efficacy of oral thin films, ensuring both therapeutic efficacy and safety. This new development has the potential to revolutionize the way oral medications are tested and administered, leading to more precise and effective treatments for a wide range of medical conditions. ...
Furthermore, this technology has the potential to significantly improve patient compliance and overall treatment outcomes. ...
By employing appropriate behavioral research methods, scientists can establish a solid foundation for studying these diseases, leading to invaluable insights and potential breakthroughs in patient care. Developed by a team of esteemed researchers, the multi-type animal cognitive behavioral tests bring together cutting-edge technology, rigorous methodologies, and diverse animal ...
In the ever-evolving field of pharmaceuticals, CD Formulation has emerged as a major player in developing innovative drug delivery systems aimed at enhancing the efficacy and safety of therapies. Through its expertise in various cutting-edge technologies such as microneedle and thin film technologies, transdermal patches, microencapsulation, and nanoparticle development, CD Formulation is ...
(“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (“mRNA”). Dyadic is a global biotechnology company focused on building ...
By engineering these cells to express specific receptors on their surface, they acquire enhanced targeting capabilities against malignant cells, giving rise to personalized treatment options with great therapeutic potential. CD Formulation's expertise extends beyond the development of CAR-T and CAR-NK cells; it also encompasses their optimization for drug ...
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, ...
Creative Proteomics, a prominent provider of proteomics services, has recently unveiled its highly anticipated Far-Western Blot Analysis service. This service has the potential to transform our understanding of complex protein-protein interactions, opening new avenues for advancements in drug discovery and therapeutic development. ...
However, the past decade has seen a growing interest in developing natural products, especially alkaloids, into potential therapeutic agents. As a matter of fact, alkaloids showed quite diverse medicinal properties, making them perfect as pharmaceutical candidates,” said one of the senior scientists from Alfa Chemistry. ...
Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of four senior leaders with significant industry experience in both small and large pharmaceutical and biotech companies. ...
With cellvie, Alex is particularly excited about the chance to contribute to what may emerge as a new treatment modality: the therapeutic use of mitochondria. Alex's presentation at the award ceremony can be watched here: About cellvie AG Started in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the ...
With >1,000 original applicants, this is a tremendous accomplishment, reflecting the interest and believe of industry experts in mitochondria-based therapies and its potential to emerge as a novel treatment modality. The award comes with $25,000 in prize money. ...
The data were presented during poster sessions at the 34th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) in Barcelona, Spain. “These early data support further investigation into the broad ...